Innova Captab IPO

Leading Market Presence: In Fiscal 2022, among Indian formulation CDMO players, Innova Captab recorded the third highest operating revenue and net profit margin. The number of CDMO products sold by the company has grown by 131.43% from 1,066 in FY '21 to 2,467 in FY '23.

Client Relationships: In CDMO business, Innova Captab has developed strong relationships across the Indian pharmaceutical industry. In Fiscal 2023, they had 182 CDMO customers. Some of our key customers include Cipla, Glenmark, Wockhardt, Emcure Pharmaceuticals Limited, Lupin Limited, Intas, Ajanta etc.

Efficient Operations: In Fiscal 2022, among Indian formulation CDMO players considered in the CRISIL Report, Innova Captab recorded second highest fixed asset turnover ratio and returns on capital employed.

Strong R&D Focus: R&D is critical to maintaining competitive position, addressing changing consumer trends and industry developments. Innova is an R&D centric organization, and our R&D operations help them attract CDMO customers and grow our branded generic portfolio. They have a dedicated R&D laboratory in Baddi, Himachal Pradesh.

Consistent Financial Performance: Company has demonstrated strong growth in terms of revenues and profitability. In Fiscal 2022, among Indian formulation CDMO players, Innova Captab recorded the third highest operating revenue, the second highest operating profit margin and the third highest net profit margin.

High Competition: Company operates in a highly competitive market. The domestic formulations industry is highly fragmented in terms of both, number of manufacturers and products, with 300 to 400 organised players and about 15,000 unorganised players. As a result, the bargaining power of contract manufacturing players is lowered owing to high competition.

Dependence on Key Customers: Business depends on a limited number of CDMO customers. Any reduction in the number of CDMO customers or inability to maintain relationships can impact revenues.

Healthcare Reforms: Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing, reimbursement and related matters could adversely affect the pricing and demand for products as well as the end consumer demand for the products,

Stringent Statutory Norms: The pharmaceutical market is subject to extensive regulation, and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could adversely affect the business.